Imaging the folate receptor on cancer cells with 99mTc-etarfolatide: properties, clinical use, and future potential of folate receptor imaging

There is no fulltext present in this item.

Title:	Imaging the folate receptor on cancer cells with 99mTc-etarfolatide: properties, clinical use, and future potential of folate receptor imaging
Author(s):	Maurer, A.H.; Elsinga, P.; Fanti, S.; Nguyen, B.; Oyen, W.J.G. ; Weber, W.A.
Publication year:	2014
Source:	The Journal of Nuclear Medicine (1978), vol. 55, iss. 5, (2014), pp. 701-704
ISSN:	0161-5505
DOI:	https://doi.org/10.2967/jnumed.113.133074
Publication type:	Article / Letter to editor
Please use this identifier to cite or link to this item : http://hdl.handle.net/2066/138222
Display more details
Subject:	Radboudumc 9: Rare cancers RIMLS: Radboud Institute for Molecular Life Sciences
Organization:	Radiology & Nuclear Medicine Nuclear Medicine
Journal title:	The Journal of Nuclear Medicine (1978)
Volume:	vol. 55
Issue:	iss. 5
Page start:	p. 701
Page end:	p. 704
Abstract:	Folate receptor (FR) can be used as a therapeutic target because of its expression on different epithelial cancers, such as ovarian, non-small cell lung, endometrial, and breast cancer. Assessing FR expression in tumors may help to identify patients who can benefit from FR-targeted therapeutics, such as vintafolide and farletuzumab. Different methods exist to detect FR expression. Tissue sampling has limited clinical utility, mainly because it requires an invasive procedure. (99m)Tc-etarfolatide, a (99m)Tc-labeled folate conjugate, is in late-phase trials in Europe and the United States. It allows noninvasive, whole-body imaging of the FR. This review focuses on this FR-imaging agent and how it may be used to direct FR-targeted therapy.